Innate response activator (IRA) B cells are a subset of B-1a derived B cells that produce the growth factors granulocyte macrophage colony stimulating factor and IL-3. In mouse models of sepsis and pneumonia, B-1a B cells residing in serosal sites recognize bacteria, migrate to the spleen or lung, and differentiate to IRA B cells that then contribute to the host response by amplifying inflammation and producing polyreactive IgM. In atherosclerosis, IRA B cells accumulate in the spleen, where they promote extramedullary hematopoiesis and activate classical dendritic cells. In this review, we focus on the ontogeny and function of IRA B cells in acute and chronic inflammation.
Introduction
When Cooper, Peterson, and Moore reported the discovery of B cells 50 years ago (1, 2), they not only settled a polarizing and heated debate on the nature of the immune system but also ushered in a new investigative era. Identifying an antibody-producing lymphocyte, distinct from T cells, that develops in a unique environment (chicken Bursa of Fabricius; human bone marrow), was the scaffold upon which the current knowledge of humoral and cellular immunity, as we know it today, was built. Over the years, landmark observations, ranging from deciphering B-cell ontogeny (3, 4) and organization within germinal centers of secondary lymphoid organs (5, 6) to characterizing immunoglobulin structure (7, 8) , V(D)J recombination (9) (10) (11) , and affinity maturation (12) (13) (14) , have concretely revealed the importance of B lymphocytes within the ever-expanding immune cell family.
Over time, we have come to appreciate that B-cell heterogeneity is a function of both vertically integrated ontogenic hierarchy (pro-B cells give rise to T1 B cells, then to T2 B cells, etc.) and environmentally-elicited horizontal diversification (memory cells, plasmablasts, and plasma cells) (15) . At the population level, arguably the most intriguing discovery was the Herzenberg laboratory's identification of a seemingly separate B-cell lineage, enriched in serosal spaces and dedicated to the production of natural antibodies (16) . Years before we knew how Toll-like receptors (TLRs) bridge the gap between innate and adaptive immunity, and decades before we appreciated that natural killer cells belong to a large innate lymphoid cell (ILC) family, here were B cells that despite definitively being 'adaptive immune' cells were apparently not connected to adaptive immunity. We refer to these cells as B-1 B cells. As opposed to the more familiar B-2 B cells that circulate and settle in B-cell follicles, B-1 B cells' spatiotemporal characteristics remain somewhat obscure. In this review, we will focus on innate response activator (IRA) B cells, a recently recognized member of the B-1 B-cell family.
IRA B cells' phenotype and ontogeny

What are they?
B cells may be exclusive antibody producers, but antibodies are not the only product of B cells. Over the last 15 years, a number of laboratories demonstrated that B cells can produce interleukin 10 (IL-10), a cytokine typically considered a T-cell product and most famous for regulating (or suppressing) inflammation (17) (18) (19) (20) (26) .
In exploring mechanisms that drive extramedullary hematopoiesis, which is the leukocyte production in locations outside the bone marrow, Rauch et al. (27) tested for the presence of granulocyte macrophage colony stimulating factor (GM-CSF) in the spleen after repeated LPS delivery to the peritoneum. GM-CSF was first observed in the 1960s, at the Walter and Eliza Hall Institute, as a product of kidney feeder cells that stimulated production of myelocytes and granulocytes, but not erythrocytes (28) . The factor was named and cloned, and the mouse knockout was eventually generated in 1994 by two independent groups (29) (30) (31) . The knockout was likely a bit of a disappointment: aside from progressive lung proteinosis, which was later shown to result from impaired surfactant clearance by alveolar macrophages, the mice were otherwise healthy, with a seemingly normal leukocyte diversity. In other words, GM-CSF was not as important to steadystate hematopoiesis as M-CSF, the closely related growth factor essential to monocytes and their descendants (32) . Nevertheless, over the years many investigators have uncovered a variety of important functions by which GM-CSF influences the host response; in aggregate, GM-CSF functions are related to myeloid leukocyte activation, differentiation and proliferation (33) . These myriad myeloid leukocyte functions impelled Rauch et al. (27) to determine the source of GM-CSF in the spleen. Using intracellular antibody staining and flow cytometry, the investigators detected a distinct population staining positive for GM-CSF comprising 1-4% of the B-cell population in the spleen 4 days after LPS administration. On their surfaces, these cells expressed CD19, B220, IgM, MHCII, CD5, CD43, CD93, CD138, VLA4, CD284 at relatively high levels. The cells were dimly positive for IgD, CD23, CD21 but negative for CD11b, CD3, Ly-6G, Ly-6C, NK1.1, CD49b, Ter119, CD4, CD8, CD11c. They were, in short, B cells, identifiable by immunofluorescence and flow cytometry and capable of producing abundant quantities of IgM. Because they produced a growth factor known to activate innate leukocytes, they were named IRA B cells (Fig. 1 ).
How do they arise?
To investigate IRA B-cell origins, Rauch et al. considered the clues: IRA B cells appeared in the splenic red pulp after LPS injection and expressed markers that closely resembled B-1 B cells, immature cells or marginal zone B cells. After performing adoptive fate mapping and parabiosis experiments; using mice lacking B cells, TLR4, Myd88, TIR-domain-containing adapter-inducing interferon-β (TRIF) or BAFF receptor (B-cell activating factor receptor); and blocking VLA4, the researchers concluded that IRA B cells derive from peritoneal B-1a B cells that relocate from the peritoneum to the spleen after recognizing LPS (the typical pathogen-associated molecular pattern) with TLR4, which signaled toward Myd88 but (34) but rely on the spleen for renewal and seeding in body cavities (35, 36) . B-1 cells also produce IgM antibodies but neither settle in germinal centers nor participate in somatic hypermutation-they are innate-like. As products of B-1 cells, IRA B cells can therefore be conceptualized both as innate responders (B cells belonging to the innate B-cell family) and response activators (producers of a factor known to activate innate myeloid cells).
IRA B cells' function
Are they important?
Identifying a GM-CSF-producing B cell that appears after LPS may be interesting per se, but evaluating that cell's importance to the host response is far more significant. Rauch et al. tested IRA B cells' function by generating mixed chimeric mice whose B cells lacked the capacity to produce GM-CSF and subjecting the animals to a model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), a life-threatening condition. Sometimes referred to as 'blood poisoning', sepsis claims up to half a million lives in USA every year (37, 38) . Its pathophysiology has confounded scientists and physicians, and several recent failed clinical trials have only underlined how incompletely we understand the condition (39). Rauch et al. discovered that mice with a B-cell-restricted GM-CSF deficiency died earlier and in larger numbers than controls, suggesting that IRA B cells are protective in sepsis. Specifically, in the absence of B-cell-derived GM-CSF, the animals developed pronounced inflammation, a cytokine storm, and more severe bacteremia, which led to septic shock, multiorgan failure and death. IRA B-cell-derived GM-CSF somehow staved off infection and curbed inflammation.
Following the identification of IRA B cells' effect on sepsis, Weber et al. (40) wished to elucidate how B-cell-derived GM-CSF might be protective. Noting that IRA B cells produce IgM and express the β common chain of the GM-CSF receptor (CD131) that is a part of the GM-CSF, IL-3 and IL-5 receptors, the investigators speculated that B-cell-derived GM-CSF controls IgM in an autocrine loop. Indeed, unlike GM-CSFdeficient and CD131-deficient B-1a B cells, wild-type B-1a B cells stimulated in vitro with LPS produced IgM and GM-CSF. Moreover, the addition of GM-CSF partially restored IgM production in GM-CSF-deficient cells. The data suggested that GM-CSF production by IRA B cells protects the host by generating polyreactive IgM that innately recognizes bacterial components and marks them for phagocyte-mediated elimination; without IgM, bacteria have more leeway to infect, proliferate, breach barriers and wreak inflammatory havoc.
If IRA B cells' GM-CSF crucially protects against polymicrobial sepsis or pneumonia, then strategies that increase the number of these cells, prevent IRA B-cell loss, amplify GM-CSF secretion or boost the IgM response could represent novel axis of treatment.
Where else do they arise?
The observation that IRA B cells differentiate from B-1a B cells in the peritoneum, which is a serosal location, led to the hypothesis that IRA B cells might also develop in other serosal sites, such as the pleural space (41, 42) . Using a model of airway infection, Weber et al. (40) showed that B-1a B cells residing in the pleural space mobilize to the lung where they produce IgM via autocrine GM-CSF signaling. Although the study did not prove that pleural B-1a B cells migrate directly across the mesothelium into the lung, cell tracking studies using intrapleural GFP + B-cell transfer revealed cell accumulation in the pleural space and lungs, but not blood, a result that supports a direct route independent of blood vessels. The study concluded that a protective leukocyte population resides outside the lungs and rapidly mobilizes after lung infection. It is unknown whether IRA B cells can mobilize from other locations, such as the pericardial space.
Are IRA B cells exclusively involved in infection?
While exploring IRA B cellular function in contexts other than infection, Hilgendorf et al. (43) observed that IRA B cells accumulate in secondary lymphoid organs of mice with atherosclerosis, the chronic lipid-driven inflammatory disease characterized by the gradual accrual of lipoproteins and leukocytes in the vessel wall (44) (45) (46) . As the underlying condition behind myocardial infarction and stroke, atherosclerosis remains by far the most lethal disease worldwide, despite the success of statins, ACE inhibitors and other drugs (47) 
CD131
-/-bone marrow, and observed that mice lacking CD131 had reduced myelopoiesis and reduced proliferation of hematopoietic stem and progenitor cells (HSPCs) in the spleen. We have previously shown that the spleen is monocyte reservoir and a major site of extramedullary hematopoiesis during chronic inflammation (51, 52) . Accordingly, Apoe -/-
-/-mice had reduced numbers of neutrophils and monocytes in the blood compared with Apoe -/-mice because of reduced medullary and extramedullary hematopoiesis, resulting in fewer cells that infiltrated the plaque.
In early atherosclerosis, when extramedullary hematopoiesis is not yet dominant, IRA B cells generate and activate splenic classical dendritic cells (DCs), which then produce IL-12, thus favoring an atherosclerosis-aggravating IFNγ-dominant
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T H 1 environment. Consequently, in the absence of GM-CSFproducing B cells, T H 1-type immunity is diminished, antibodies recognizing oxidation-specific epitopes harbor T H 2-associated Fc regions, and atherosclerotic lesions are smaller (43) .
IRA B cells may therefore be targeted to treat atherosclerosis at an early phase to diminish T H 1 type immunity and both at the early and the later phases to decrease myeloid cell production in the bone marrow and spleen.
What else do IRA B cells produce?
The gene encoding GM-CSF, located on chromosome 11 in the mouse and chromosome 5 in the human, is adjacent to the gene encoding IL-3, a cytokine identified in mice in 1981 (53, 54) and in humans in 1986 (55) . Because IL-3 is important to leukocyte production, proliferation, and survival (56) , and because of its proximity on the genome to GM-CSF, Weber Chousterman, He et al. (57) asked whether IRA B cells likewise produce IL-3. The answer was yes: IRA B cells are major sources of IL-3 in humans and mice with sepsis. To determine whether IL-3 is important in the host response to bacterial infection, Weber, Chousterman, He et al. subjected
Il3
-/-mice to CLP. Compared with wild-type mice, Il3 -/-mice were protected from sepsis, and the differences between the groups remained significant even when they were given antibiotics. Mechanistically, IL-3 promoted the production of inflammatory monocytes and neutrophils, which are the cell sources of the cytokine storm associated with severe sepsis and septic shock that causes organ damage and death. Thus, IRA B cells and their IL-3 product are upstream sentinels and amplifiers of acute inflammation. Significantly, a clinical trial on nearly 100 septic patients revealed that high IL-3 levels in plasma associated with high mortality even after investigators adjusted for various prognostic indicators. The data collectively show that IRA B cells can be both protective and detrimental in sepsis depending on the cytokine they produce. Although GM-CSF protects against sepsis by producing neutralizing antibodies with broad specificities, IL-3 can dangerously over-produce inflammatory cells. Thus, diminishing IL-3 production while conserving GM-CSF synthesis may be essential when dealing with treatments focused on the positive and detrimental contributions of IL-3 on the pathogenesis of this disease.
Conclusions and ongoing questions
As producers of potent growth factors, IRA B cells significantly contribute to immunity and inflammation. Moving forward, many questions remain. Why are B cells the major producers of GM-CSF and IL-3 in bacterial infection? For example, in the steady state, intestinal type 3 ILCs (58) and lung epithelial cells (59) produce GM-CSF. Clearly neither GM-CSF nor IL-3 are exclusive to B cells, yet, under some conditions, B cells become these growth factors' major sources. Could the BCR play a role in driving growth factor transcription, perhaps by integrating signals with those downstream of pattern recognition receptors? Moreover, what is the ultimate fate of IRA B cells? Are they nothing more than short-lived plasmablasts, or do they have functions beyond those first several days, perhaps related to memory or trained immunity? Can they eventually class-switch? Do they produce other growth factors? Do they have a role in autoimmune disease such as arthritis or multiple sclerosis? These and other questions will be critical over the next several years for anyone interested in deciphering the scope of this B-1 subset.
